



PRESS RELEASE

Indoco's annual revenues grow by 7.6 %

Mumbai, May 16, 2024: During the fourth quarter of FY 2023-24, revenues of Indoco Remedies grew by 1.7 % at Rs. 4,351 mn, as against Rs. 4,280 mn, same quarter last year. EBIDTA to net sales for the quarter is 13.2 % at Rs. 574 mn, compared to 15.0 % at Rs. 642 mn, same quarter last year. Profit After Tax to net sales is 8.6 % at Rs. 376 mn, compared to 5.9 % at Rs. 254 mn, same quarter last year.

For the year, revenues grew by 7.6 % at Rs. 17,619 mn, as against Rs. 16,381 mn, same period last year. EBIDTA to net sales for the period is 14.6 % at Rs. 2580 mn, compared to 17.4 % at Rs.2849 mn, same period last year. Profit After Tax to net sales is 6.6 % at Rs. 1166 mn, compared to 8.6 % at Rs. 1414 mn, same period last year.

Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd. said, “Indoco is set to take a big leap based on the various strategic decisions taken during this year. We are optimistic to improve our performance in the coming quarters.”

About Indoco Remedies Limited:

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company's turnover is US\$ 212 million with a human capital of over 6000 employees, including over 400 skilled scientists and Field Staff who are the strength of the organization.

The Company has 11 manufacturing facilities, 7 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 106 million prescriptions annually from over 2,35,000 doctors belonging to various specialties. Indoco has 8 domestic marketing divisions a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynecology etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Aloja, Glychek, Kidodent, Subital, Rexitin,

MCBM 69, Methycal, Dropizine, Noxa, Homide, Cal-Aid, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:



Mr. Anuj Sonpal
Valorem Advisors
Tel: +91-22-4903-9500
Email: indoco@valoremadvisors.com